Salix Pharmaceuticals Sets New 52-Week High at $103.67 (SLXP)
Salix Pharmaceuticals (NASDAQ:SLXP) hit a new 52-week high on Tuesday , Analyst Ratings Network.com reports. The company traded as high as $103.67 and last traded at $102.36, with a volume of 781,618 shares trading hands. The stock had previously closed at $100.98.
A number of research firms have recently commented on SLXP. Analysts at Roth Capital raised their price target on shares of Salix Pharmaceuticals from $106.00 to $110.00 in a research note on Friday. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Salix Pharmaceuticals in a research note on Monday, January 20th. They now have a $103.00 price target on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Salix Pharmaceuticals to $115.00 in a research note on Friday, January 17th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have issued a buy rating to the stock. Salix Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $90.80.
The stock’s 50-day moving average is $94.97 and its 200-day moving average is $79.44. The company has a market cap of $6.439 billion and a price-to-earnings ratio of 60.00.
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.